MaxCyte to acquire Akron Bio, expanding cell therapy manufacturing offerings
MXCT•MaxCyte will acquire Akron Bio for $151.8 million and expects the deal to nearly double its revenue base. Akron Bio is expected to generate about $28 million in 2026 revenue and $7 million to $8 million in EBITDA.
1. Acquisition details
MaxCyte will fund the acquisition with cash on hand and newly issued common stock, and will pay $20 million in guaranteed deferred payments. It also secured a new credit facility of up to $75 million. Akron Bio is expected to continue operating under its existing brand.
